This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: BIIB's Q3 Earnings, REGN's COVID-19 Cocktail Update & More
by Zacks Equity Research
Regulatory and pipeline updates from bigwigs like Regeneron (REGN) and Biogen (BIIB) have been the biotech sector's few key highlights during the past week.
Roche (RHHBY) 9M21 Sales Grow on Strong COVID-19 Tests, View Up
by Zacks Equity Research
Roche (RHHBY) posts an encouraging performance in the third quarter and the first nine months of 2021 driven by demand for coronavirus tests due to the Delta variant and recovery in pharma sales.
Esperion (ESPR) to Cut 40% Workforce, Revamp Cost Structure
by Zacks Equity Research
Esperion (ESPR) is set reduce its workforce by 40% and start targeted program savings to reduce its operational expense and deliver consistent growth.
Gilead's (GILD) Biktarvy Gets FDA Nod for Pediatric Patients
by Zacks Equity Research
Gilead (GILD) wins FDA approval for the label expansion of HIV treatment Biktarvy for the pediatric patient population.
Zacks.com featured highlights include: Regeneron Pharm, Evercore, Houlihan Lokey and DICK'S Sporting Goods
by Zacks Equity Research
Zacks.com featured highlights include: Regeneron Pharm, Evercore, Houlihan Lokey and DICK'S Sporting Goods
Has Regeneron Pharmaceuticals (REGN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (REGN) Outperforming Other Medical Stocks This Year?
Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on sales of new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports third-quarter earnings.
Biogen's (BIIB) Tofersen Reports Mixed Data From ALS Study
by Zacks Equity Research
Biogen's (BIIB) phase III study evaluating tofersen for ALS with SOD1 mutation fails to meet the primary endpoint of the study. However, the study shows signs of reduced disease progression with tofersen.
Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Gilead's (GILD) application for breast cancer drug gets positive opinion for approval from EMA's CHMP.
4 Top-Ranked Stocks to Invest in for Solid Earnings Growth
by Tirthankar Chakraborty
Regeneron Pharmaceuticals (REGN), Evercore (EVR), Houlihan Lokey (HLI) & DICK'S Sporting Goods (DKS) currently have striking earnings growth and positive estimate revisions, which make them must-buys.
Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Regeneron (REGN) closed at $547.12, marking a +0.49% move from the previous day.
bluebird (BLUE) Gives Details on Oncology Business Spinoff
by Zacks Equity Research
bluebird (BLUE) provides information on stock distribution ratio and cash allocation for the planned spin-off of the oncology business.
J&J (JNJ) Seeks Stelara Label Expansion in Juvenile Arthritis
by Zacks Equity Research
J&J (JNJ) files a regulatory application, seeking the label expansion of its inflammatory drug, Stelara, as a potential treatment of juvenile psoriatic arthritis.
5 Finest PEG Stocks Based on Hybrid Investment Strategy
by Urmimala Biswas
Here are five out of the 14 stocks, TSCDY, REGN, DGX, EQNR and MAKSY that qualified the screening.
4 Reasons to Add Regeneron (REGN) Stock to Your Portfolio
by Zacks Equity Research
Regeneron (REGN) is expected to gain from a solid and diverse portfolio despite stiff competition for its key drugs. The promising pipeline also sets the stage for growth further.
Fortress' (FBIO) Partner Meets Study Goal for Menkes Disease
by Zacks Equity Research
Cyprium Therapeutics, a partner company of Fortress Biotech (FBIO), reports positive data from two pivotal studies evaluating CUTX-101 in patients with Menkes disease.
3 Reasons Why Growth Investors Shouldn't Overlook Regeneron (REGN)
by Zacks Equity Research
Regeneron (REGN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
ChemoCentryx (CCXI) Tavneos Gets FDA Nod for ANCA Vasculitis
by Zacks Equity Research
The FDA approves ChemoCentryx's (CCXI) lead drug Tavneos to treat ANCA-associated vasculitis. It is the company's first drug to get FDA approval. Resultantly, the stock gains in pre-market trading.
Amgen (AMGN) Reports New Data From Lumakras Combo Study
by Zacks Equity Research
Amgen (AMGN) reports new combination data from the phase Ib CodeBreaK 101 study. It also buys a stake in Neumora Therapeutics to advance novel therapies for brain diseases.
Should Value Investors Buy Regeneron (REGN) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
REGN or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
REGN vs. TECH: Which Stock Is the Better Value Option?
Zacks.com featured highlights include: T. Rowe Price, Best Buy, Celanese Corp, CBRE Group and Regeneron Pharma
by Zacks Equity Research
Zacks.com featured highlights include: T. Rowe Price, Best Buy, Celanese Corp, CBRE Group and Regeneron Pharma
4D Molecular (FDMT) to Start Studies on Cystic Fibrosis, Wet AMD
by Zacks Equity Research
4D Molecular (FDMT) is set to initiate studies for gene-therapy candidates to treat cystic fibrosis lung disease and wet AMD, following FDA clearance of its two IND applications.
Voyager (VYGR) Surges on Gene Therapy Deal With Pfizer
by Zacks Equity Research
Voyager (VYGR) signs agreement with Pfizer granting the latter with rights to develop novel capsids using Voyager's proprietary technology for Pfizer's gene therapies and options for exclusive license to the capsids.
5 High ROE Stocks to Buy as Markets Face Intense Volatility
by Supriyo Bose
T. Rowe Price Group (TROW), Best Buy (BBY), Celanese Corporation (CE), CBRE Group (CBRE), and Regeneron Pharmaceuticals (REGN) are some of the stocks with high ROE to buy in a volatile market.